Dignify Therapeutics, LLC — SEC Form D Filing

Dignify Therapeutics, LLC filed an SEC Form D on September 25, 2026, reporting $800K raised in Pharmaceuticals.

Form D filing details

Filing
SEC Form D
Filing date
September 25, 2026
Amount reported
$800K
Round stage
Seed, because an $800,000 debt round is typical for an early-stage pharmaceutical company funding preclinical validation and initial regulatory filings.
Industry
Pharmaceuticals
Website
https://dignifytherapeutics.com

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Patients suffering from spinal cord injuries, multiple sclerosis, and spina bifida experience neurogenic bladder and bowel dysfunction, stripping them of their independence and causing frequent, severe urinary tract infections.

Solution

Dignify Therapeutics is developing novel, on-demand pharmaceutical compounds designed to restore voluntary bladder and bowel voiding without the need for invasive catheterization.

Why now

Recent breakthroughs in targeting specific neurotransmitter receptors coincide with an urgent regulatory and clinical push to reduce catheter-associated urinary tract infections in healthcare facilities.

Source: SEC EDGAR Form D filing